◀ Back to CD79B
AMN — CD79B
Text-mined interactions from Literome
Weisberg et al., Cancer Cell 2005
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive...) :
Characterization of
AMN107 , a selective
inhibitor of native and mutant
Bcr-Abl
Golemovic et al., Clin Cancer Res 2005
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
AMN107 , a novel aminopyrimidine
inhibitor of
Bcr-Abl , has in vitro activity against imatinib-resistant chronic myeloid leukemia
Kantarjian et al., Ann Intern Med 2006
(Disease Progression...) :
In light of the limitations of imatinib against these factors, newer tyrosine kinase inhibitors, including dasatinib ( a multitargeted kinase inhibitor of BCR-ABL and Src family kinases ) and nilotinib (
AMN107 , a selective
BCR-ABL inhibitor ), may provide promising treatment options for patients with CML